newsroom.

We are pleased to announce that Jackie Beltrani has joined Cosette Pharmaceuticals as Director, Commercial Operations. Jackie will report to Kian Kazemi and will be based in the Bridgewater office.

Apurva Saraf, President and CEO of Cosette, stated "This launch is further evidence of Cosette’s ability to partner globally and bring important drugs to the market, and furthers our transformation into a specialty pharmaceutical company.  We stay true to our firm belief of Innovating Every Day, to be a trusted partner of choice, and to continue the important work of serving U.S. patients and prescribers.”

Cosette Pharmaceuticals, Inc ("Cosette") announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for Metronidazole Gel USP, 1%.

Cosette Pharmaceuticals, Inc began shipping Griseofulvin Oral Suspension, 125 mg/5 mL (0713-0850-04) into all channels in the United States.

“We are very excited to have Kevin Hickey join our team. His tremendous experience in strategy and execution of branded products will be instrumental as we integrate our eight cardio branded products through our transformative acquisition from Daiichi Sankyo and get ready for the imminent launches of several new products and lifecycle management strategies.” said Apurva Saraf, President and CEO, Cosette Pharmaceuticals.

Cosette announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Applications (ANDA) for the first generic versions of TAZORAC® (tazarotene) gel, 0.05% and 0.1%, with 180 days Competitive Generic Therapy (CGT) exclusivity. Cosette has already commenced commercial shipments, triggering the 180 days exclusivity.

Ganesh Pillarisetti has joined the executive team as Vice President, IT at Cosette Pharmaceuticals. Ganesh will report to our President and CEO, Apurva Saraf, and will be based out of our office at South Plainfield, New Jersey. In this critical role, Ganesh's expertise in leveraging IT to streamline processes to increase both efficacy and efficiencies in our core areas of manufacturing, supply chain, quality, finance etc. will help us strongly deliver on our growth strategy of inorganic and organic growth through relentless execution.

Bridgewater, NJ. July 6, 2022. Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, today announced the appointment of Rick Casten as Chief Financial Officer (CFO), bolstering its executive leadership team.

BRIDGEWATER, NJ – JUNE 7, 2022: Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, announced today that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,291,628 for Welchol® Chewable Bar, the Company’s novel drug delivery system of Colesevelam that is easy to handle and ingest, which provides patent protection until 2037.

Bridgewater, NJ and Vadodara, India May 24, 2022/PRNewswire/Cosette Pharmaceuticals, Inc ("Cosette"), in collaboration with Aleor Dermaceuticals, a wholly owned subsidiary of Alembic Pharmaceuticals (“Alembic”; BSE: 533573), announced that the U.S. Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for an NBE version of Abreva® (Docosanol cream 10%) in a 2 gm tube and pump formats. Shipments of the product will begin imminently.

Cosette Pharmaceuticals, Inc., a New Jersey-based pharmaceutical company, today announced the launch of Prochlorperazine Edisylate injection, 10 mg/2ml (5mg/ml).

Cosette Pharmaceuticals, Inc., a New Jersey-based specialty pharmaceutical company, announced today that it has closed a transaction to acquire the US sales and distribution rights to eight branded commercial products from leading Japanese pharmaceutical company, Daiichi Sankyo Company, Ltd (4568:JP) and affiliates.

We are pleased to announce Mindy Hanna has joined Cosette Pharmaceuticals as Senior Director, Human Resources.  Mindy will report to Apurva Saraf and will be based in the South Plainfield office.

Solaris Pharma Corporation (“Solaris” or the “Company”) announced today that the Company has received an abbreviated new drug application (“ANDA”) approval from the U.S. Food and Drug Administration (“FDA” or “Agency”) for the first generic version of Clindagel® (clindamycin phosphate EQ 1%). This product will be manufactured in the United States by Cosette, Solaris’ manufacturing partner. The product will be launched immediately.

Cosette Pharmaceuticals, Inc., a New Jersey-based specialty generic pharmaceutical company, has received a first cycle approval of the Company’s abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration (FDA) of Hydrocortisone Valerate Cream USP, 0.2%. This is Cosette’s first approval for 2021 from its internally-developed pipeline of prescription pharmaceutical products.

We are very pleased to welcome Apurva to the Cosette team. His deep knowledge of the pharmaceutical industry, along with his corporate strategy and business development experience, will be of great value as Cosette continues to expand its portfolio of differentiated complex products, both internally and through strategic collaborations,” stated Sriram Venkataraman, Partner of Avista Capital Partners.